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The heterodimeric haemoprotein soluble guanylate
cyclase (sGC) is the direct sensor and mediator of nitric
oxide (NO) signal transduction via the NO-sGC-cGMP
pathway. Aberrant sGC-dependent signalling may be fun-
damental to the aetiology of a wide variety of cardiovascu-
lar pathologies. As a consequence, compounds that
activate cGMP production by sGC have a considerable
therapeutic potential.
To date, x-ray structures of independent sGC domains
HNOX, HNOX-A and GC have been solved. Nevertheless,
the determination of the full-length sGC x-ray structure
would provide additional clues to understand the struc-
tural basis for the mechanism of sGC assembly and regu-
lation and should facilitate the design of these therapeutic
agents.
To achieve this goal, I developed a heterologous expres-
sion system of full-length bovine sGC (Fl-sGC). Early
attempts to produce recombinant bovine sGC in E. coli
resulted in misfolded protein accumulation. Indeed, pro-
ducing soluble protein in Escherichia coli is still a major
difficulty in the sGC field. By using fusion technology, I
successfully overexpressed both α and β subunits in a sol-
uble heme-bound active form. Optimization of expres-
sion levels by varying bacterial growth conditions
including temperature, media, additives and induction,
will be followed by purification and characterization of
Fl-sGC. So, a crucial step has been achieved, allowing us
to pursue structural studies to probe the structure and
mechanism of sGC and promote the discovery of stimula-
tors of this physiologically important enzyme.
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